Coexpression of EGFr, HER2, HER3 and HER4 in primary human breast carcinoma

Witton, Caroline; Reeves, J R; Going, JJ; Cooke, Timothy G.; Bartlett, John M.S.

doi:10.1016/s0959-8049(01)80096-4

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The majority of these trials, however, did not select their patients prospectively on the basis of EGFR expression status and were small, and therefore any subgroup benefit may not have been detected. We have previously shown that other members of the HER2 gene family may influence response to therapy and clinical outcome, 9,11,40,49 and results from single‐agent studies with lapatinib, a small‐molecule inhibitor of EGFR and Her2 tyrosine kinases and dimerization inhibitor, in which patients are treated on the basis of biomarker expression, are promising 50 . Given the increasing knowledge of Her family biology, similar hypothesis‐driven enrichment of patient populations to be treated with EGFR inhibitors should also be carried out, and detection and interpretation of EGFR standardized.…”

Section: Drug‐driven Tissue Biomarker Discoverymentioning

confidence: 99%

Predictive markers in breast cancer – the future

Faratian

Bartlett

2007

Histopathology

View full text Add to dashboard Cite

The published literature is awash with examples of new tissue biomarkers promising to predict responses to therapy in breast cancer patients. However, few, if any, of these progress from the laboratory to the clinic. In this review we discuss some of the reasons for this, illustrating our discussion with a selection of biomarkers which are in development and which may be candidates for clinical application within the next few years (topoisomerase II alpha, epidermal growth factor receptor, AKT, phosphatase and tensin homologue). In particular, we explore how our ever increasing knowledge of molecular and pathway biology is facilitating hypothesis-driven biomarker discovery, and the statistical considerations which need to be addressed in order to validate new candidate biomarkers adequately.

show abstract

Section: Drug‐driven Tissue Biomarker Discoverymentioning

confidence: 99%